PORTAGE BIOTECH INC (PRTG)
VGG7185A1286 - Common Stock
Taking everything into account, PRTG scores 2 out of 10 in our fundamental rating. PRTG was compared to 568 industry peers in the Biotechnology industry. The financial health of PRTG is average, but there are quite some concerns on its profitability. PRTG is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
PRTG had negative earnings in the past year.
PRTG had a negative operating cash flow in the past year.
In the past 5 years PRTG always reported negative net income.
In the past 5 years PRTG always reported negative operating cash flow.
1.2 Ratios
With a Return On Assets value of -1357.19%, PRTG is not doing good in the industry: 99.65% of the companies in the same industry are doing better.
PRTG's Return On Equity of -2830.59% is on the low side compared to the rest of the industry. PRTG is outperformed by 84.25% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1357.19% | ||
| ROE | -2830.59% | ||
| ROIC | N/A |
ROA(3y)-360.91%
ROA(5y)-218.97%
ROE(3y)-674.91%
ROE(5y)-409.17%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
PRTG does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
Compared to 1 year ago, PRTG has less shares outstanding
The number of shares outstanding for PRTG has been reduced compared to 5 years ago.
PRTG has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -66.27, we must say that PRTG is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -66.27, PRTG is doing worse than 95.40% of the companies in the same industry.
PRTG has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -66.27 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
PRTG has a Current Ratio of 1.73. This is a normal value and indicates that PRTG is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.73, PRTG is doing worse than 79.29% of the companies in the same industry.
PRTG has a Quick Ratio of 1.73. This is a normal value and indicates that PRTG is financially healthy and should not expect problems in meeting its short term obligations.
PRTG has a worse Quick ratio (1.73) than 78.23% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.73 | ||
| Quick Ratio | 1.73 |
3. Growth
3.1 Past
The earnings per share for PRTG have decreased strongly by -403.10% in the last year.
EPS 1Y (TTM)-403.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
PRTG is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.77% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y99.49%
EPS Next 2Y41.28%
EPS Next 3Y25.91%
EPS Next 5Y14.77%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
PRTG reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year PRTG is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PRTG's earnings are expected to grow with 25.91% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.28%
EPS Next 3Y25.91%
5. Dividend
5.1 Amount
No dividends for PRTG!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
PORTAGE BIOTECH INC
NASDAQ:PRTG (12/20/2024, 8:00:01 PM)
After market: 5.87 -0.09 (-1.51%)5.96
+0.11 (+1.88%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners10.77%
Inst Owner Change-100%
Ins Owners33%
Ins Owner ChangeN/A
Market Cap6.26M
Analysts43.33
Price TargetN/A
Short Float %1.28%
Short Ratio0.01
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.49 | ||
| P/tB | 2.49 | ||
| EV/EBITDA | N/A |
EPS(TTM)-129.8
EYN/A
EPS(NY)-0.53
Fwd EYN/A
FCF(TTM)-11.94
FCFYN/A
OCF(TTM)-11.94
OCFYN/A
SpS0
BVpS2.39
TBVpS2.39
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1357.19% | ||
| ROE | -2830.59% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-360.91%
ROA(5y)-218.97%
ROE(3y)-674.91%
ROE(5y)-409.17%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.73 | ||
| Quick Ratio | 1.73 | ||
| Altman-Z | -66.27 |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-403.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y99.49%
EPS Next 2Y41.28%
EPS Next 3Y25.91%
EPS Next 5Y14.77%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y7.99%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-70.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-70.29%
OCF growth 3YN/A
OCF growth 5YN/A